Previous 10 | Next 10 |
Detection of elevated FABP5 associated with additional tumor types suggests the target for ART26.12 may be more broadly relevant in cancer therapy Alderley Park Oncology Development Program is a UK program designed to develop and progress innovative oncology projects ...
LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that ...
Gainers: Enveric Biosciences (ENVB) +86%, MediciNova (MNOV) +53%, Artelo Biosciences (ARTL) +23%, Inari Medical (NARI) +15%.Losers: INVO Bioscience (INVO) -34%, Second Sight Medical Products (EYES) -26%, Sintx Technologies (SINT) -23%, Au...
MediciNova (MNOV) +87% on BARDA partnership for Ibudilast development.Cemtrex (CETX) +85%.Koss Corporation (KOSS) +50%.Obalon Therapeutics (OBLN) +34%.Enveric Biosciences (ENVB) +39% on agreement to acquire exclusive license for novel molecules from Diverse Biotech.MoneyGram Interna...
Clinical stage biopharmaceutical company Artelo Biosciences (ARTL) shares rise nearly 22% premarket after announcing the appointment of Tamara Seymour to the company’s board of directors.Seymour is a corporate finance veteran with three decades of exp...
Will March Continue to be Bullish For These Penny Stocks? So far in March, certain penny stocks have seen some big bullish interest. On March 9th, the NASDAQ rallied up by around 4% during intraday trading. These gains were led by tech, as a large rebound occurred following a market cor...
LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announc...
LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorga...
Artelo Biosciences (ARTL) rises 20% premarket following data showing potential pharmacodynamic interactions of co-administration of cannabidiol ((CBD)) and tetramethylpyrazine ((TMP)) in cell-based models of cancer.The research focused on the components of Artelo’s CBD:TMP co...
LA JOLLA, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) today announced that Saoirse O’Sullivan, Ph.D., Professor of Pharmacology and Scientific Advisor to Artelo, along with Ryan Maguire and Dr. Timothy England of the Univ...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- A...
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...